A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients

Part of paid clinical trials in East Hanover, New Jersey.

Sponsor
Novartis Pharmaceuticals
Study ID
NCT07408219
Status
Recruiting
Apply to this trial

Conditions

  • Chronic Spontaneous Urticaria

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Study Details

This is a United States (US) based, prospective, non-interventional, provider-referral study to evaluate the real-world effectiveness and patient-centered outcomes of remibrutinib in chronic spontaneous urticaria (CSU) patients using validated patient reported outcome (PRO) tools.

Key Dates

Start date
Jan 17, 2026
Status verified
May 2026
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
350 participants (estimated)

Arms

  • Arm: Remibrutinib Cohort
    Adult patients with CSU who are prescribed and initiating treatment with remibrutinib.
  • Arm: Dupilumab Cohort
    Adult patients with CSU who are prescribed and initiating treatment with dupilumab.

Primary Outcome Measure

Change From Baseline in Urticaria Control Test - 7 Day Recall (UCT-7) Score at Week 4 in Patients Initiating Remibrutinib [ Time Frame: Baseline and Week 4 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
NovartisEast HanoverNew Jersey07936-

Find similar trials in East Hanover, NJ

By research site
Novartis· East Hanover, NJ

Related Studies